This website uses cookies to enhance the user experience.
G

GENTIAN AS979 819 234

Research
Limited company
Bjørnåsveien 5 1596 MOSS, Norge

GENTIAN AS

Keywords

researchdevelopment workbiotechnologygenomicspharmageneticsgene samplesdna sequencingdna synthesisdna deepeninggenetic engineeringproteinsmoleculespeptide sequencinglipidglycotechniqueproteomicshormonesgrowth factorscell receptorspheromonescell culturetissue culturecrossingcell fusionvaccineimmunostimulatorsembryo manipulationprocess biotechnologybioreactorsfermentationbioprocessingbiorecoverybiodesulfurizationbiological pulp productionbiofiltrationbiological regenerationsubcellular organismsgene therapyvirusesvectors

Links

Organization

CEO
Chairman of the board
Years since formation
27 years
since May 5, 1998
Type
Limited company
VAT registered
Yes
Number of employees
50

Ownership

Number of shares and share classes
15,000,000
1 share class
Total number of shareholders
1
company
Belongs to group of

Financials

Total operating income 2024
138,044,747
NOK
Annual total result 2024
60,333,027
NOK
Total equity 2024
128,967,030
NOK
Last update: May 26, 2025

Management

Management / administration

NameRoleShares
Managing Director/CEO-

Board

NameRoleShares
Chairman-

Others

NameRoleShares
B
BDO AS
Auditor-
A
AZETS INSIGHT AS
Accountant-

Top 10 individual shareholders

NameRoleShares
-
13.68 %
indirectly
-
7.81 %
indirectly
-
4.86 %
indirectly
-
3.56 %
indirectly
-
2.4 %
indirectly
-
2.4 %
indirectly
-
2.12 %
indirectly
-
1.54 %
indirectly
-
1.38 %
indirectly
-
1.35 %
indirectly
Last update: May 15, 2024

Ownership

Company shareholders

NameShare classTotal number of sharesShare
G
GENTIAN DIAGNOSTICS ASA
Ordinary shares
15,000,000
100 %
Last update: May 24, 2024

Group structure

  • Total operating income 2024: NOK 1,604,000
    Operating profit 2024: NOK -10,168,403
    Employees: 0

Financials

in NOK

Summary

Year2024202320222021
Total operating income
138,044,747
118,224,537
96,421,779
85,257,579
Annual Total Result
60,333,027
-1,772,208
-13,089,728
-11,390,103
Total assets
179,418,295
111,011,472
124,502,834
113,541,415
Total liabilities
50,451,264
103,960,476
116,124,293
93,684,130
Total equity
128,967,030
7,050,996
8,378,542
19,857,285

P&L

Year2024202320222021
Total operating income
138,044,747
118,224,537
96,421,779
85,257,579
Total operating costs
99,517,339
116,361,709
105,620,895
94,189,719
Operating result
38,527,407
1,862,827
-9,199,116
-8,932,140
Financial income/costs
-3,423,577
-3,635,035
-3,890,612
-2,457,963
Profit before tax
35,103,830
-1,772,208
-13,089,728
-11,390,103
Total tax & extraordinary income/cost
-25,229,197
0
0
0
Annual Total Result
60,333,027
-1,772,208
-13,089,728
-11,390,103

Balance overview

Year2024202320222021
Total fixed assets
78,057,591
48,339,902
55,867,282
51,862,075
Total current assets
101,360,704
62,671,570
68,635,552
61,679,341
Total assets
179,418,295
111,011,472
124,502,834
113,541,415
Short term debt
26,586,751
18,242,608
18,463,500
15,049,813
Long term debt
23,864,514
85,717,869
97,660,792
78,634,317
Total liabilities
50,451,264
103,960,476
116,124,293
93,684,130
Contributed capital
75,000,000
15,000,000
15,000,000
18,898,693
Retained earnings
53,967,030
-7,949,004
-6,621,458
958,592
Total equity
128,967,030
7,050,996
8,378,542
19,857,285
Total equity and liabilities
179,418,295
111,011,472
124,502,834
113,541,415

Classification

Category
Type of organization
Limited company
Classification of institutional sector
INNL
Domestic sectors
A_IKKE-FIN
Non-financial corporations
2100
Private non-financial incorporated enterprises
Standard industrial classification
M
Main industrial area
Professional, scientific and technical activities
72
Activity
Scientific research and development
72.1
Main industrial group
Research and experimental development on natural sciences and engineering
72.11
Industrial group
Research and experimental development on biotechnology
72.110
Industrial group
Research and experimental development on biotechnology